Gliclazide is an oral antihyperglycemic agent used for the treatment of diabetes mellitus type II. It belongs to the sulfonylurea class of secretagogues, which stimulates β cells of the pancreas to release. Gliclazide binds to the β cell sulfonyl urea receptor (SUR1), further blocking the ATP sensitive potassium channels. Therefore, the potassium efflux substantially decreases, causing depolarization of the β cells. Then the voltage-dependent calcium channels in the β cell are open, resulting in calmodulin activation, which in turn leads to exocytosis of containing secretorty granules. Recent studies have also shown that gliclazide can effectiveimprove anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes and protect pancreatic beta-cells from damage.

Gliclazide lowers your blood sugar.
Gliclazide is used when diet, exercise, and weight reduction have not been found to control blood glucose well enough without medication. 
Reduce platelet aggregation and adhesion, prevent fibrin deposition on capillaries.
Reduce cholesterol accumulation, reduce the blood plasma concentration of arterial triphosphate and fatty acid.
In addition to treating diabetes metabolic disorders.
Prevent and treat diabetic complications-the occurrence and development of vascular, retina, and renal dysfunction.